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ABSTRACT
Selective serotonin reuptake inhibitor (SSRI) use is common among ovarian 
cancer patients. We examined the effect of SSRIs on survival and progression 
in ovarian cancer patients and effects of 5-HT on ovarian cancer cell (OCC) 
proliferation. Ovarian cancer patients from a 6-site study between 1994 and 2010 
were included. Cox proportional hazards models were used for multivariate analysis. 
SSRI use was associated with decreased time to disease recurrence (HR 1.3, CI 
1.0-1.6, p=0.03), but not overall survival (HR 1.1, CI 0.9-1.3, p=0.56). Compared 
to normal ovarian cells, most OCCs had elevated 5-HT2A receptor mRNA expression 
(up to 1600 fold greater expression). Clonogenic survival increased in cells treated 
with 10 uM (1.6 fold, p<0.001) and 20uM (1.9 fold, p=0.018) 5-HT. Mice receiving 
5-HT injections had increases in tumor weight (p=0.07) and nodules (p=0.08) with 
increased Ki67 expression. Injections with sertraline doubled mean tumor weight 
in mice (p=0.16). 5-HT and sertraline both increased Ki67 expression in mouse 
tumors (p < 0.001).
Patients using SSRIs had significantly decreased time to disease progression. It is 
possible that SSRIs alter serotonin levels in the tumor microenvironment, resulting in 
activation of proliferation pathways. Further characterization of serotonergic pathways 
in ovarian cancer is recommended to demonstrate safety of these medications.
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INTRODUCTION
Depression is common in ovarian cancer patients, 
with a recent study reporting that 55% of newly diagnosed 
patients suffer from clinical or subclinical depression. 
[1] Management of depression is important in oncology 
patients as it may negatively impact quality of life, [2, 3] 
adherence to medical regimens, [4] decision making [5] 
and cancer outcomes. [6, 7] Antidepressants are commonly 
prescribed to treat depression in cancer patients. Current 
clinically used antidepressants include but are not limited 
to selective serotonin-reuptake inhibitors (SSRIs), 
serotonin norepinephrine-reuptake inhibitors (SNRIs), and 
tricyclic antidepressants (TCAs). [8] It is unclear how best 
to manage depression in cancer populations since there 
have been reports that antidepressants, specifically SSRIs 
and TCAs, may promote tumor growth in preclinical 
experimental models for various cancers. [9-12]
Animal experiments have demonstrated inhibition of 
lymphocyte proliferation and growth-promoting effects of 
SSRIs on mammary tumors, melanoma, and fibrosarcoma. 
[13] However, results from experimental studies are 
inconsistent. [14] Fluoxetine (20-80 mg/kg) promoted 
fibrosarcomas (mice), melanomas (mice) and mammary 
carcinogenesis (rats). [13, 14] In contrast to these findings, 
fluoxetine (10-20 mg/kg) demonstrated antineoplastic effects 
on chemically induced colonic tumors in rats. [14] Fluoxetine 
(30mg/kg) has also been shown to reduce colon cancer 
development in rats. [12] The potential for antidepressants 
to promote tumor growth has led to various epidemiologic 
studies examining the risk of developing cancer among 
antidepressant users. There have been inconsistent findings 
with respect to risk of developing ovarian cancer among 
antidepressant users, [15-22] although meta-analysis revealed 
a modest increased risk of breast and ovarian cancer with the 
use of antidepressants, especially SSRIs. [22]
Antidepressants have been designed to alter 
serotonergic pathways. Serotonin (5-hydroxytryptamine (5-
HT)) performs a variety of functions as a neurotransmitter 
with roles in mood, homeostatic regulation, and intestinal 
motility. Many of its functions in the periphery are relevant 
to tumor development. 5-HT has shown mitogenic effects 
on several carcinomas including breast cancer cells 
[23], human pancreatic carcinoid cells [24], rat colonic 
adenocarcinoma [25] and human small cell lung carcinoma 
[26]. 5-HT signaling is initiated through interaction with a 
receptor subtype from one of seven receptor families, the 
majority of which are G-coupled transmembrane proteins 
from families 1 and 2. [27] Immunohistochemistry has 
revealed the presence of 5-HT receptors in several tumor 
types, including ovarian. [28]
Peripheral 5-HT in the blood is carried by platelets 
and released in high concentrations (micromolar) during 
degranulation events. [29] Platelets possess the serotonin 
transporter (SERT), allowing them to uptake 5-HT across 
their plasma membrane with further transport into dense 
granules via a monoamine transporter. [30] Selective-
serotonin reuptake inhibitors (SSRIs) are designed to 
increase 5-HT levels in the synaptic cleft by inhibiting SERT 
reuptake of 5-HT. Outside of their designed function, SSRIs 
decrease reuptake of 5-HT by platelets through binding of 
SERT. [30, 31] Consequences of changes to peripheral 
5-HT regulation are poorly understood and have important 
implications regarding tumor growth in cancer patients.
To date, no studies have examined effects of SSRIs 
among patients already diagnosed with ovarian cancer 
and the influence SSRIs may have on survival and disease 
progression in these patients. Moreover, no studies have 
explored the effect of 5-HT or SSRIs on ovarian neoplastic 
cell growth. To address these knowledge gaps, we 
characterized 5-HT receptor expression in ovarian cancer 
cells and investigated the functional and biological roles 
of 5-HT using in vitro and in vivo models. In addition, 
this multicenter study examined effects of SSRIs on 
survival and disease progression in patients diagnosed 
with epithelial ovarian cancer.
RESULTS
Patient characteristics
Demographic and clinical characteristics of the sample 
are listed in Table 1. The median patient age was 60.1 (IQR, 
52 to 68) years. The median follow-up duration was 56.4 
(IQR, 31.2 to 85.2) months for all patients: 60.0 (IQR, 34.8 
to 86.4) months for antidepressant users and 62.4 (IQR, 
39.6 to 82.8) months for SSRI users. Patients predominantly 
had advanced stage (82%) and high-grade (81%) disease, 
with serous histology (76%). A majority of patients (64%) 
had received optimal cytoreduction. Antidepressants were 
used by 26% of patients. The most commonly used class of 
antidepressants was SSRIs (16%) followed by SNRIs (6%), 
TCAs (3%). Sertraline was the most commonly prescribed 
SSRI (n=34), followed by fluoxetine (n=30), escitalopram 
(n=25), paroxetine (n=23) and citalopram (n=18). Four 
percent of patients (n=28) used two different antidepressant 
classes. Only SSRIs were analyzed separately due to small 
sample size for other classes of antidepressants. Comparison 
of patient characteristics showed that antidepressant users 
were more likely to be white (97% vs. 87%, p<0.001) and 
had a slightly lower percentage with suboptimal residual 
disease (31% vs. 38%, p=0.07) than patients not using 
antidepressants. There was no significant difference in 
age (p=0.16), stage (p=0.84), grade (p=0.11), histology 
(p=0.74), or duration of follow-up (p=0.19). Similar results 
were observed comparing characteristics of SSRI users and 
patients not using SSRIs.
Univariate survival analyses
Univariate analyses indicated that age, stages III 
and IV disease, suboptimal cytoreduction, high grade 
Oncotarget33181www.impactjournals.com/oncotarget
and serous histology were significantly associated with 
both shorter survival time and time to disease recurrence 
(Supplementary Table S2). Neither use of antidepressants 
nor use of SSRIs was significantly associated with survival 
or progression.
Multivariate model
Cox multivariate regression was performed to 
examine adjusted risks of survival in ovarian cancer 
patients. Adjusting for disease stage, grade, histology, 
Table 1: Patent characteristics
All patients (N=773) Patients on ADs (n=203) Patients on SSRIs (n=125)
Characteristic No. % No. % No. %
Age (years)
  Median 60.1 59.0 59.7
  IQR 52-68 50.3-67 51-67
FU duration, months
  Median 54.8 58.8 62.5
  IQR 31.4-85.3 33.5-83.2 37.7-83.2
Race
  White 679 91.6 183 97.3 115 97.5
  Other 62 8.4 5 2.7 3 2.5
Stage
  I 78 10.2 23 11.3 16 12.8
  II 60 7.8 15 7.4 10 8.0
  III 549 71.9 147 72.4 88 70.4
  IV 77 10.1 18 8.9 11 8.8
Residual Disease
  Optimal 492 63.7 140 69.0 87 69.6
  Suboptimal 281 36.4 63 31.0 38 30.4
Grade
  High 627 81.4 173 85.2 105 84.0
  Low 143 18.6 30 14.8 20 16.0
Histology
  Serous 582 75.5 155 76.4 93 74.4
  Other 189 24.5 48 23.6 32 25.6
ADs 203 26.3 203 100.0 125 100.0
SSRIs 125 16.2 125 61.6 125 100.0
SNRIs 44 5.7 44 21.7 7 5.6
TCAs 24 3.1 24 11.8 3 2.4
NDRIs 18 2.3 18 8.9 5 4.0
SARIs 11 1.4 11 5.4 3 2.4
NaSSAs 9 1.2 9 4.4 3 2.4
Abbreviations: ADs, antidepressants; FU, follow-up; IQR, interquartile range; NaSSAs, noradrenergic and specific serotonergic 
antidepressants; NDRIs, norepinephrine-dopamine reuptake inhibitors; SARIs, serotonin antagonist-reuptake inhibitors; SNRIs, 
selective norepinephrine-reuptake inhibitors; SSRIs, selective serotonin-reuptake inhibitors; TCAs, tricyclic antidepressants.
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residual disease, and age, there was no difference in 
time to death or progression between patients using vs. 
not using antidepressants (all p-values > .50) (Table 2). 
Similarly, there was no difference in overall survival 
between patients using vs. not using SSRIs (p=0.56). 
However, multivariate analysis did reveal a significantly 
decreased time to disease progression in SSRI users vs. 
non-users (HR=1.3, 95% CI 1.0-1.6; p=0.03). In addition, 
logistic regression revealed a possible trend towards an 
increased risk of progression in SSRI users (OR 1.44, CI 
0.9-2.3, p=0.12), although not statistically significant.
5-HT receptor expression and proliferation
Given the association of SSRI use with shorter time 
to disease progression, we next asked whether cancer 
cells could be impacted directly by SSRIs. All OCC lines 
expressed mRNA for 5-HT receptor subtypes 1A, 1B, 
1D, and 2A (Figure 1). Only 2 OCCs (2774 and CaOV3) 
expressed subtype 1E mRNA; 1F was not observed in any 
of the cell lines investigated. Compared to normal ovarian 
cells, 8 out of 9 OCCs had elevated 5-HT2A receptor 
mRNA expression (up to 1600 fold greater expression; 
p-values <0.001).
Clonogenic survival was significantly increased in 
SKOV3 cells (Figure 2) after treatment with 10 uM (1.6 
fold, p<0.001) and 20 uM (1.9 fold, p=0.018) 5-HT. DOI, 
a potent 5HT2A receptor agonist, increased clonogenic 
survival in SKOV3 cells at 10 uM (1.4 fold, p=0.014) 
and 20 uM (1.4 fold, p=0.14) doses. Survival was also 
significantly increased in CP20 cell proliferation after 
treatment with 20 uM 5-HT (1.16 fold, p<0.001) and 20 
uM DOI (1.17 fold, p<0.001) but was not changed by 
10 uM 5-HT (p=0.79) or 10uM DOI (p=0.18). ES2 cell 
proliferation was increased by 10 uM 5-HT (1.17 fold, 
p<0.01) and 20 uM 5-HT (1.20 fold, p<0.01). ES2 cell 
proliferation was not changed by 10 uM DOI (p=0.43) 
and 20 uM (p=0.13). The magnitude of increased survival 
was greatest in SKOV3 cells compared to CP20 and ES2 
cells. ES2 cell survival demonstrated an increasing trend 
of survival with 20uM DOI, but the results were not 
significant.
In vivo mouse experiments
To examine potential in vivo effects of 5-HT and 
sertraline, we used an orthotopic mouse model of ovarian 
cancer. Sertraline was selected for in vivo experiments 
because it was the most commonly used antidepressant in 
our patient sample. Following treatment with either 5HT 
or sertraline, mice received an intraperitoneal injection of 
SKOV3 cancer cells. 5-HT 10 mg/kg injections increased 
tumor weight (p=0.07) (Figure 3A) and number of nodules 
(p=0.08) (Figure 3B). No difference was observed with 1 
mg/kg doses. Consistent with our in vitro findings, Ki67 
was significantly increased by both 1 mg/kg (p<0.001) 
and 10 mg/kg (p<0.001) dosing with no change observed 
in CD31 or caspase 3 (Figure 3C). Tumor weight 
doubled after 10 mg/kg sertraline injections, although 
not statistically significant (p=0.16) (Figure 3D) with 
no change seen in number of tumor nodules (p=0.78) 
(Figure 3E). Ki67 was significantly increased by 10 mg/
kg (p<0.001) dosing with no change observed in CD31 or 
caspase 3 (Figure 3F).
DISCUSSION
Key findings of this study are that SSRIs are 
associated with a decreased time to disease progression 
after adjusting for significant covariates, although they 
are not associated with overall survival. The effect size 
of 5-HT on cell survival was variable depending on the 
cell line studied. There is substantial variability in patient 
tumor composition between individuals that could account 
for some of the insignificant and modestly significant 
findings described in this study. These findings are the 
first to indicate the use of SSRIs among ovarian cancer 
patients may impact disease progression. The present 
study is unique as the majority of studies on antidepressant 
use have focused on its relationship to risk of developing 
cancer. A recent meta-analysis of 61 studies examined 
the relationship between antidepressants and the risk of 
developing breast or ovarian cancer and reported a small 
but statistically significant increase in the risk for breast 
and ovarian cancer in women who use SSRIs. [22] The 
effects of antidepressants on survival and progression 
have been minimally examined in clinical populations; 
existing studies have tended to focus on breast cancer 
patients concurrently using tamoxifen. [37] Tamoxifen 
has been explored as an ovarian cancer therapy, [38, 39] 
and inhibition of CYP2D6 by some SSRIs (most notably 
fluoxetine and paroxetine) could reduce effective 
tamoxifen utilization in ovarian cancer patients through 
decreased generation of active metabolites. Through drug 
interactions and direct effects on the tumor cells, there 
may be specific implications to antidepressant selection 
in cancer patients.
5-HT was shown to have a mitogenic effect on 
OCCs that was partially mediated by the 5-HT2A receptor. 
5-HT2A receptor mRNA was upregulated in OCCs 
compared to normal ovarian epithelial cells, supporting a 
physiologic role of 5-HT in OCC growth. In vivo results 
demonstrated increased tumor burden with upregulation of 
Ki67, indicating 5-HT signaling is coupled to proliferation. 
We also demonstrated that sertraline promotes cell 
proliferation by upregulating Ki67. In human endothelial 
cells, 5-HT has been shown to activate angiogenic 
phosphorylation signaling. [40] Neither 5-HT or sertraline 
increased CD31, an angiogenic marker, or caspase 3, 
apoptotic marker, in our study. Both 5-HT and sertraline 
demonstrate mitogenic effects on ovarian neoplastic cells 
through similar cellular signaling pathways. Our results 
support a mechanism by which SSRIs may promote 
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Table 2: Multivariate cox proportional hazard ratios for antidepressant use, overall survival, and PFS in ovarian 
cancer patients
Covariate All ADs SSRIs
Progression Death Progression Death
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age
(unit = 10 yrs) 1.1 1.1-1.2 0.20 1.2 1.1-1.3 <0.001 1.1 1.0-1.1 0.20 1.2 1.1-1.4 <0.001
Stage v I
  II 1.6 0.9-2.9 0.09 1.1 0.5-2.4 0.83 1.6 0.9-2.9 0.09 1.1 0.5-2.5 0.80
  III 3.9 2.5-6.1 <0.001 3.2 1.8-5.9 <0.001 4.0 2.5-6.2 <0.001 3.3 1.8-5.9 <0.001
  IV 5.5 3.3-9.2 <0.001 4.9 2.5-9.3 <0.001 5.6 3.3-9.3 <0.001 5.0 2.6-9.5 <0.001
RD v optimal
  Suboptimal 1.9 1.6-2.3 <0.001 2.1 1.7-2.6 <0.001 2.0 1.6-2.4 <0.001 2.1 1.7-2.6 <0.001
Grade v low
  High 1.2 0.9-1.5 0.16 1.1 0.9-1.5 0.34 1.2 0.9-1.5 0.19 1.1 0.9-1.5 0.38
Histol v other
  Serous 1.1 0.9-1.4 0.27 1.0 0.8-1.4 0.73 1.1 0.9-1.4 0.26 1.0 0.8-1.4 0.77
AD v non-use
  Use 1.1 0.9-1.3 0.51 1.0 0.8-1.2 0.70 1.3 1.0-1.6 0.03 1.1 0.8-1.4 0.56
Abbreviations: AD, antidepressant; Histol, histology; PFS, progression-free survival; RD, residual disease; SSRI, selective 
serotonin-reuptake inhibitor; yrs, years.
Figure 1: Relative 5HTR (families 1 and 2) mRNA expression of 9 OCC lines (SKOV3, HEYA8, 2774, ES2, TOV112D, 
OV90, SW626, UWB1.298 and CaOV3) compared to normal ovarian cells on a log scale. Compared to normal ovarian cells, 8 
out of 9 OCC lines had elevated 5HTR2A mRNA expression (up to 1600 fold greater expression). Results represented as the mean +/- SEM.
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Figure 2: Clonogenic survival assays in SKOV3, CP20 and ES2 cells. Increased SKOV3 proliferation was observed after 
treatment with 10 uM (1.6 fold, p<0.001) and 20 uM (1.9 fold, p=0.018) 5-HT. DOI increased SKOV3 survival at 10 uM (1.4 fold, p=0.014) 
and 20 uM (1.4 fold, p=0.14) doses. CP20 cell proliferation increased with 20 uM 5-HT (1.16 fold, p<0.001) and 20 uM DOI (1.17 fold, 
p<0.001) but was not changed by 10 uM 5-HT (p=0.79) or 10uM DOI (p=0.18). ES2 cell proliferation was increased by 10 uM 5-HT (1.17 
fold, p<0.01) and 20 uM 5-HT (1.20 fold, p<0.01). ES2 cell proliferation was not changed by 10 uM DOI (p=0.43) and 20 uM (p=0.13). 
Results represented as the mean +/- SEM.
growth of residual neoplastic disease through altered 5-HT 
levels in the tumor microenvironment, thereby decreasing 
time to disease progression.
Growing evidence supports the involvement of 5-HT 
and SSRIs in immune system interactions. 5-HT is also an 
important mediator of immune cell signaling, promoting 
neutrophil recruitment [41] and cell signaling of mast 
cells and lymphocytes. [42, 43] SSRIs have been shown to 
depress immune cell function, largely suspected to be the 
result of decreased platelet 5-HT concentrations. After 3 
weeks of effective dosing, SSRIs decrease blood serotonin 
content by 90% and inhibit platelet reuptake of 5-HT. [44] 
There is accumulating evidence that platelet release of 
5-HT is involved in inflammatory processes, including 
joint edema. [45] Suppressed lymphocyte proliferation 
was observed after SSRI administration in vivo. [46] By 
compromising optimal immune function, SSRIs may allow 
tumor cells to evade detection and cytotoxic killing.
This study contributes to the growing body of research 
supporting further characterization of serotonergic effects of 
medications in cancer patients. These findings are potentially 
relevant for other classes of medications. Numerous other 
serotonergic agents are commonly used in ovarian cancer 
patients, such as certain analgesics (e.g. tramadol), antibiotics 
(e.g. linezolid) and antihistamines (e.g. diphenhydramine). 
These medications have the potential to affect 5HT levels and 
SERT activity. The clinical relevance of their serotonergic 
effects on tumor biology is currently unknown. Much like 
monoamine oxidase inhibitors (MAOIs), linezolid inhibits 
monamine oxidase nonselectively increasing neurotransmitter 
levels. Other neurotransmitters have been shown to have 
systemic functions relevant to tumor biology. Tumor growth 
has been shown to be promoted by norepinephrine and 
inhibited by dopamine. [47, 48] Selective norepinephrine-
reuptake inhibitors (SNRIs), tricyclic antidepressants 
(TCAs), norepinephrine-dopamine reuptake inhibitors 
(NDRIs) and noradrenergic and specific serotonergic 
antidepressants (NaSSAs) increase levels of norepinephrine, 
and NDRIs increase levels of dopamine. It is unknown how 
antidepressants affect the levels of these neurotransmitters at 
the tumor site. The systemic impact of antidepressants and 
their influence on the tumor microenvironment are important 
considerations for future research.
Strengths
This is the first study to examine the affects of 
antidepressants on progression and survival in ovarian 
cancer patients. Data were compiled from multiple medical 
centers resulting in a large sample size with adequate power 
to detect clinically significant differences. Antidepressant 
use at time of surgery was available through medical 
records reducing the possibility of recall bias.
Limitations
An important limitation of this study is the lack of 
information on duration and dose of antidepressant use. 
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Figure 3: In vivo mouse experiment in 8- to 12- week old female athymic nude mice administered daily 5-HT or 
sertraline injections. A. 5-HT 10mg/kg injections increased tumor weight (p=0.07). B. 5-HT 10 mg/kg injections increased number of 
nodules (p=0.08). (Continued )
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Figure 3: (Continued ) In vivo mouse experiment in 8- to 12- week old female athymic nude mice administered daily 
5-HT or sertraline injections. C. Ki67 was significantly increased at 1 mg/kg (p<0.001) and 10 mg/kg (p<0.001) 5-HT. D. Sertraline 
10 mg/kg injections increased tumor weight 2-fold (p=0.16). (Continued )
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Figure 3: (Continued ) In vivo mouse experiment in 8- to 12- week old female athymic nude mice administered daily 
5-HT or sertraline injections.  E. Sertraline injections at 10 mg/kg was not associated with an increase in number of tumor nodules. 
F. Ki67 was significantly increased with 10 mg/kg (p<0.001) sertraline injection. Results represented as the mean +/- SE.
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Patients were classified as antidepressant users or non-users 
based on medical record information at the time of surgery. 
Information on previous use of antidepressants and length 
of use was not available. This study also did not explore 
dose effects of antidepressants on ovarian cancer patient 
outcomes, and this is an important question for future 
research. The study was unable to account for discontinued 
use or de novo use of antidepressants during the follow-
up period. Information on the success of antidepressant 
treatment was also unavailable. Unsuccessful treatment 
of depression could contribute to poor outcomes in cancer 
patients. This study is unable to differentiate between risk of 
death from antidepressant use versus depression.
This study found that ovarian cancer patients 
using SSRIs had decreased time to disease progression. 
At this time, more data on duration of antidepressant 
use in diagnosed cancer populations would be important 
to further clarify these findings. More research is 
recommended to understand the mechanisms behind the 
possible contribution of SSRIs to circulating serotonin 
levels and influence on the tumor microenvironment. 
Examination of associations between cancer survival and 
different classes of antidepressants, including SNRIs, 
TCAs, and aminoketones (such as bupropion) also have 
potential clinical relevance. There may be direct drug 
effects as well as modifications to serotonin levels that 
contribute to risk of cancer recurrence.
MATERIALS AND METHODS
Patient data
Study population
Records of women (n=773) diagnosed with ovarian 
cancer at six study sites (University of Iowa Hospital 
and Clinics (n=192), University of Miami (n=21), Mercy 
Medical Center (Miami) (n=2), Washington University 
(n=12), MD Anderson Cancer Center (n=270), and Mercy 
Medical Center Baltimore, MD (n=276)) were examined. 
Approval from institutional review boards of all recruitment 
sites was obtained prior to patient enrollment, and all 
participants provided written informed consent. Ovarian 
cancer was confirmed by histological diagnosis of primary 
invasive epithelial ovarian, peritoneal or fallopian tube 
cancer (stages I through IV were included) at time of 
upfront surgical debulking. A minimum of 6-month patient 
follow-up was required for inclusion in the study. Patients 
were excluded if another organ site was the location of the 
primary cancer or if the primary cancer was not epithelial. 
At the Iowa, Miami, and Washington University sites, where 
accrual was part of a larger investigation of psychosocial 
factors and biomarkers, patients were excluded if they had 
used systemic corticosteroid medications in the month 
before surgery, if they had comorbidities known to alter the 
immune response, or were under 18 years of age.
Clinical information including age, grade, stage, 
histology, extent of cytoreduction, antidepressant use, 
progression and survival was obtained from medical 
records. Antidepressant use was based on current 
medication use at the time of surgery. Patient recruitment 
and censoring occurred over the different dates based on 
site: Universities of Iowa and Miami and Mercy Medical 
Center (Miami) from 2003 to 2010 (censored June 2011), 
Washington University from 2009 to 2010 (censored 
June 2011), MD Anderson from 1994 to 2008 (censored 
December 2010), and Baltimore from 1994 to 2009 
(censored May 2011). The longest follow-up duration 
was 18 years for the earliest recruited Baltimore patients. 
Progression-free survival was defined as the time between 
surgery and the first recurrence (if complete response), or 
progression, as defined by GCIG and RECIST criteria. 
[32] Overall survival was measured from the date of 
surgery until date of death. [33] Information was missing 
on death for 3 patients and on progression for 7 patients.
Statistical analysis
SAS 9.3 was used for all analyses of the clinical 
study data. Descriptive patient characteristics were 
compiled and differences examined using X2 and Fisher’s 
exact tests for categorical variables and independent 
samples t tests for continuous variables. Median follow-
up duration was calculated using the inverse Kaplan-
Meier method. Two sets of analyses were performed 
on progression and survival; one tested use of all 
antidepressants with progression and survival, the second 
tested use of SSRIs with progression and survival. The 
association of survival time with antidepressant use 
and with each potential covariate was examined using 
univariate Cox proportional hazard regression models. 
[34] From the fitted Cox models, the unadjusted hazard 
ratio with 95% confidence intervals was obtained, and 
significance of the association was tested using the Wald 
Chi-square statistic. Covariates included in univariate and 
multivariate analyses were stage (advanced-stage: III, 
IV vs. early-stage: I, II), grade (high vs. low), residual 
disease (suboptimal vs. optimal cytoreduction <1cm), 
histology (serous vs. non-serous), and age. Standard 
diagnostics were utilized to evaluate model adequacy. [35] 
Statistical significance was set at p < 0.05 and all analyses 
were two-tailed.
Power analysis
With the study sample size, there is an 80% power 
to detect an 8.5% decline in time to disease progression 
with use of antidepressants and 10% decline in time to 
progression with use of SSRIs. There is an 80% power to 
detect a 9.5% decline in survival with use of antidepressants 
and 11% decline in survival with use of SSRIs.
Cell culture
Ovarian carcinoma cell lines (A2780-CP20, SKOV3, 
HEYA8, 2774, ES2, TOV112D, OV90, SW626, UWB1.298 
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and CaOV3) and normal ovarian cells were cultured in 
RPMI-1640 media supplemented with 15% fetal bovine 
serum and 0.1% gentamicin. A2780-CP20 (labeled CP20) 
cells were developed by sequential exposure of A2780 
cells to cisplatin of increasing concentrations. Cells were 
obtained from the institutional Cell Line Core laboratory 
and authentication performed once per year according to 
institutional policy (MD Anderson ACA#1044) using the 
Promega Power Plex 16HS kit (Promega). Mycoplasma 
screening was performed with the MycoAlert Kit (Lonza). 
Cells were maintained in an incubator at 37°C in 5% CO2.
Real-time RT-PCR assays for gene expression
Quantitative real-time RT-PCR was used to 
determine 5HT receptor mRNA expression. Total cellular 
RNA was isolated using RNeasy Mini Kit (Qiagen, 
Valencia, CA, USA) and quantified using a biophotometer 
(Eppendorf, Westbury, NY, USA). Reverse transcription to 
yield cDNA for real-time RT-PCR analysis was performed 
using a High Capacity cDNA Archive Kit (Applied 
Biosystems Inc., Foster City, CA, USA). The reverse 
transcription reaction of 2 ug of RNA was primed with 
random primers and incubated at 25C for 10 min followed 
by 37C for 120 min. The primer/probe PCR reactions 
consisted of 80 ng of cDNA added to 12.5 ul of TaqMan 
Universal PCR Master Mix (Applied Biosystems Inc.), 
1.25 ul gene-specific primer/probe mix, and 6.25 uL PCR 
grade water, for a 25 uL total reaction. Primers for all of 
the serotonin receptor subtypes in families 1 and 2 were 
designed using Roche Universal ProbeLibrary and ABI 
primer express software (Supplementary Table S1). The 
PCR conditions for all reactions were 95C for 10 min, 
followed by 40 cycles of 95C for 15s, with annealing 
at 60C for 1 min. Real-Time PCR was performed on an 
ABI 7000 real-time sequence detection system. Gene-
specific TaqMan probes were labeled with a 5’ reporter 
dye, 6-FAM, and a 3’ end containing a nonfluorescent 
quencher and a minor groove binder. Fold differences 
in OCC mRNA expression relative to normal ovarian 
cells were calculated using their respective mRNA 
expression calibrated to 18-s ribosomal RNA expression 
and computed using ABI relative quantitative software 
(Applied Biosystems Inc.). MCF-7 and PC3 cells served 
as positive controls for 5HT2A [23] and 5HT1A and B 
[36] receptor expression respectively.
Clonogenic survival assays
On 60mm tissue culture dishes, cells (SKOV3, 
CP20 and ES2) were plated to reach 80 percent 
confluency after 72 hours. After 48 hours, cells were 
treated with 5-HT or 2,5-dimethoxy-4-iodoamphetamine 
(DOI), a potent 5HT2A receptor agonist, using one of 
the following conditions: culture media (untreated), 
10 uM 5-HT, 20 uM 5-HT, 10 uM DOI, or 20uM DOI. 
Cells were incubated in culture media, 5HT or DOI for 
24 hours. Cells were then treated with TrypLE Express 
(1X), counted with a hemacytometer and then plated at 
concentrations of 500 and 1000 cells per plate. Colonies 
were grown for 14 days and then stained with Coomassie. 
Colonies >50 cells were counted to determine the 
normalized surviving fraction (NSF). Surviving fraction 
(SF) = (colonies counted)/(cells plated); NSF = (SF of 
the clonogenic survival plate)/(average SF of fraction 
of untreated plates). Each condition was performed in 
triplicate and replicated 3 times.
In vivo mouse experiments
Female athymic nude mice between 8 to 12 weeks 
old were obtained from the National Cancer Institute. All 
experiments were approved by the Institutional Animal 
Care and Use Committee at M. D. Anderson Cancer 
Center. Mice were administered daily 5-HT i.p. injections 
at 1 mg/kg and 10 mg/kg doses. For SSRI experiments, 
sertraline 10mg/kg was injected i.p. instead of 5-HT. 
Tumor cells, 1x106 SKOV3, were injected i.p. into 
mice, 10 mice per group, 3 days post-initiation of 5HT 
or sertraline treatments. Daily 5-HT i.p. administration 
continued for the duration of the experiment. Animals 
were necropsied 4 weeks after tumor cell inoculation. At 
this time, the entire peritoneal cavity was examined for 
identifiable disease. Mouse weight, tumor weight, number 
of nodules and distribution of tumor was recorded by 
gynecologic oncologists. Tissue was stained for Ki67, a 
proliferation marker, CD31, an indicator of microvessel 
density, and caspase 3, an apoptotic marker, and quantified 
based on number of stained cells per 20x field. Control 
mice received PBS injections, the solvent used for 5-HT 
and sertraline.
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